What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
The Lancet Infectious Diseases·
- DOI
- 10.1016/s1473-3099(20)30773-8
- PMID
- 33125914
- PMCID
- PMC7837315
- OpenAlex
- W3088489318
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The article frames direct evidence of human vaccine efficacy as important for selecting vaccines for wider manufacture and for reducing COVID-19 morbidity and mortality. Its relevance is methodological and contextual rather than evidence of an observed population-level effect.
Structured evidence summary
Research question
The review examines how to define and assess clinical efficacy for COVID-19 vaccines, including which outcomes best indicate protection against SARS-CoV-2 infection and COVID-19.
Study design
This is a narrative review discussing vaccine-efficacy assessment challenges, interpretation of efficacy endpoints, and considerations for phase 3 clinical trials.
Population and setting
The subject is human evaluation of candidate SARS-CoV-2 vaccines, with particular attention to phase 3 trials assessing protection against infection, disease, transmission, severe disease, and death.
Main findings
The review identifies infection, disease, and transmission as possible vaccine-effectiveness targets, while describing protection against severe disease and death as the most important but difficult endpoint to assess in phase 3 trials. It also emphasizes that reported efficacy estimates require careful interpretation.
Public-health relevance
The article frames direct evidence of human vaccine efficacy as important for selecting vaccines for wider manufacture and for reducing COVID-19 morbidity and mortality. Its relevance is methodological and contextual rather than evidence of an observed population-level effect.
Important limitations
The supplied evidence is a review abstract and bibliographic record rather than the full article, so detailed methods, source selection, and any author-stated limitations cannot be assessed. The original paper is required for decision-grade interpretation.
GIDS interpretation
The article is discoverable under vaccination and vaccine-effectiveness topics and provides context for interpreting COVID-19 vaccine efficacy endpoints. It does not establish or validate a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 14 auditable classifier relationships to diseases, places, topics, and study design.